iRhythm Technologies (Nasdaq:IRTC) posted first-quarter results that beat the consensus forecast on Wall Street and increased its outlook for the rest of the year, sending the stock up more than 10% by this morning.
The San Francisco-based developer of remote external electrocardiogram monitors reported a net loss of $50.6 million, or -$1.71 per share, on sales of $92.4 million for the three months ended March 31, 2022.
That was a 24.3% increase in sales and a smaller loss than the -$27.8 million (or -$0.95 per share) reported in Q1 2021.
Get the full story at our sister site, Medical Design & Outsourcing.
This story originally ran on May 5, 2022. Updated May 6 with the next-day stock price.